
Impax Asset Management Group plc
("Impax" or the "Company")
Directorate Changes
Keith Falconer to retire as Chairman; Sally Bridgeland appointed as successor; Simon O'Regan appointed Non-Executive Director
Sally Bridgeland has been appointed as Chair with effect from 8 December 2020 as Keith's successor. Sally became a Non-Executive Director of Impax in 2015 and has worked in the
Commenting on his plans, Keith Falconer said:
"I have had the honour of serving as Chairman since 2004. Over this time Impax has grown its assets under management from
Sally Bridgeland said:
"I am delighted to assume the role of Chair at such an exciting point in Impax's history. I am very much looking forward to building on Keith's work alongside my fellow Board members to deliver long-term success for the Company and create value for all our stakeholders.
"The commitment of policy makers, business leaders and wider society to forging a path towards a more sustainable economy has never been stronger. Against this backdrop, Impax's well-established investment philosophy, broad range of investment solutions and acknowledged leadership position will stand the Company in good stead to deliver further value to clients over the coming years."
Sally Bridgeland will step down from the Audit & Risk Committee, on which she serves as Chair. This position will be assumed by Vince O'Brien, who will step down as Chairman of the Remuneration Committee. Lindsey Brace Martinez will replace Mr O'Brien as Chair of the Remuneration Committee.
Ian Simm, Chief Executive of Impax, said:
"I would like to thank Keith for his inspiring leadership, his advice and dedication to Impax during his time as Chairman. His business acumen and judgement have greatly contributed to our success, and he will be sorely missed!
"I am very pleased that Sally is taking over as Impax's Chair. Since she joined the Board in 2015, Sally has made a tremendous contribution to the Company's strategic development both as an Independent Non-Executive Director and as Chair of the Audit & Risk Committee."
Appointment of Non-Executive Director: Simon O'Regan
Impax is pleased to announce the appointment of William Simon O'Regan to the Board as Non-Executive Director, effective 8 December 2020. Simon will sit on the Company's Audit & Risk and Remuneration Committees. Simon was previously CEO of Mercer's US business before his retirement in 2017. He was also a member of the
Ian Simm, Chief Executive of Impax, said:
"On behalf of the Board, I'm delighted to welcome Simon O'Regan, who is a highly-experienced investment industry Non-Executive Director and business leader. Simon's in-depth knowledge of international markets, including
Simon O'Regan said:
"This is an exciting time to be joining the Impax Board. As the Company's recent results show, Impax is enjoying a very strong period of growth with significant potential to expand further in international markets. I look forward to working with Ian, Sally and the rest of the Board to support the next chapter in its story."
During the last five years immediately preceding the date of this announcement, Simon O'Regan, who is 61 years old, held the following directorships:
· Mercer Africa Limited - Current
· Alexander Forbes Group Holdings Ltd - Current
· Mercer Limited - Ceased in 2020
· Mercer Ireland Holdings Ltd - Ceased in 2020
· Mercer Holdings Inc - Ceased in 2017
· Mercer (US) Inc - Ceased in 2017
· CPSG Partners LLC- Ceased in 2017
There is no further information required to be disclosed pursuant to paragraph (g) of Schedule 2 of the AIM Rules.
LEI number: 213800AJDNW4S2B7E680
- Ends -
Enquiries:
Impax Asset Management Group plc Ian Simm, Chief Executive Paul French, Corporate Communications Director
|
+44 (0)20 3912 3000 |
Montfort Communications Gay Collins Louis Supple
|
+44 (0)77 9862 6282 +44 (0)77 3943 0102 |
Peel Hunt LLP, Nominated Adviser James Britton or Rishi Shah |
+44 (0)20 7418 8900 |
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.